(Q35720552)

9 August 2017

1 reference

title

Prostate-specific antigen and screening for prostate cancer (English)

1 reference

9 August 2017

1 reference

Misop Han

1

1 reference

PubMed ID

15049577

9 August 2017

Peter H Gann

series ordinal

2

1 reference

PubMed ID

15049577

9 August 2017

William J Catalona

series ordinal

3

1 reference

9 August 2017

1 March 2004

1 reference

Medical Clinics of North America

9 August 2017

1 reference

9 August 2017

88

1 reference

9 August 2017

2

1 reference

9 August 2017

245-65, ix

1 reference

Precipitating antigens of the normal human prostate.

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Prostatic origin of tumors. An immunohistochemical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

"BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Lowering PSA cutoffs to enhance detection of curable prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Measurement of complexed PSA improves specificity for early detection of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5' promoter region of the gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

The Nature of Prostate Cancer Detected Through Prostate Specific Antigen Based Screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Design and evolution of the data management systems in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

The European Randomized Study of Screening for Prostate Cancer (ERSPC)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Prostate cancer screening in the Tyrol, Austria: experience and results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Prostate cancer screening in Tyrol, Austria: experience and results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900188-3

10.1016/S0025-7125(03)00188-3

7 January 2021

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

15049577